Acta Scientific Cancer Biology (ASCB)

Mini Review Volume 4 Issue 2

A Challenge to Artificial Intelligence: Find Molecular Structures Uniquely and Functionally Connected to the Initiation and Progression of Diseases

Karel Petrak D Phil*.

Matrx Pharmaceuticals, Inc, USA.

*Corresponding Author: Karel Petrak D Phil, Matrx Pharmaceuticals, Inc, USA.

Received: December 09, 2019; Published: January 07, 2020

×

Abstract

   Artificial Intelligence (AI) could make a major contribution to the development of disease-targeted drug delivery by elucidating what drives diseases at the molecular level, and in particular what unique molecular structures are involved that are not shared by non-disease cells. To this end, AI will need to acquire the manner of processing information in human-thinking terms such as perception, abstraction and memories, apply critical analysis of the information and then remember and recall outcomes as and when needed to synthesize a new, more complex whole. Ultimately, it will need to have the capacity to generate new knowledge and know-how.

Keywords: Molecular Structures; Progression

×

References

  1. Wong C., et al. “Corrigendum: Estimation of clinical trial success rates and related parameters”. Biostatistics 20.2 (2018): 273-286.
  2. Lin A., et al. “Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials”. Science Translational Medicine 11.509 (2019).
  3. SEER Cancer Statistics Review (2015).
  4. Austreid E., et al. “The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy”. Expert Opinion on Pharmacotherapy 15.5 (2014): 681-700. 
  5. Petrak K. “Visions but Not False Promises Should Be Funded”. Developing Drugs Journals 5 (2016): 154. 
  6. Petrak K. “Targeting Drug-Delivery Systems: Promises, Promises, and More Promises”. Let's Change the Paradigm in Recent Advances in Drug Delivery Research (2013): 167-180. 
  7. Petrak K. “A New Paradigm for Developing Effective Anti-Cancer Therapeutics”. Cancer Therapy and Oncology International Journal 4.5 (2017): 555649. 
  8. Pramanik N., et al. “A Composite of Hyaluronic Acid-Modified Graphene Oxide and Iron Oxide Nanoparticles for Targeted Drug Delivery and Magnetothermal Therapy”. ACS Omega 4.5 (2019): 9284-9293. 
  9. Petrak K. “Essential properties of drug-targeting delivery systems”. Drug Discovery Today 10.23-24 (2005): 1667-1673. 
  10. Boddy A., et al. “Efficiency of drug targeting: steady-state considerations using a three-compartment model”. Pharmaceutical Research 6 (1989): 367-372.
  11. Petrak K. “Disease-Target Drug Delivery - Science or Fiction?” Journal of Cancer Science and Treatment 1.1 (2018): 101.
  12. Petrak K. “The difference between targeted drug therapies and targeted-drug therapies”. Medical and Clinical Research Reports 1.1 (2018). 
  13. Petrak K. “The Complex Challenge of Targeted Therapy in Cancer". Acta Scientific Cancer Biology 3.6 (2019): 08-13.
  14. Walker J. Machine Learning Drug Discovery Applications – Pfizer, Roche, GSK, and More (2019).  https://emerj.com/ai-sector-overviews/machine-learning-drug-discovery-applications-pfizer-roche-gsk/  
  15. Buvailo A and Ajami A. Top 7 Trends in Pharmaceutical Research In (2018). 
  16. Buvailo A. “Brings A Surge of Activity in the “AI for Drug Discovery” Space (2018). 
  17. Darzalex® (Daratumumab) Is Now Approved Across Newly Diagnosed Patients with Multiple Myeloma (2019). 
  18. Petrak K. “The difference between targeted drug therapies and targeted-drug therapies”. Medical and Clinical Research Reports 1.1 (2018): 5-8. 
  19. Krupansky J. How Close Is AI to Human-level Intelligence Here in (2018). 
×

Citation

Citation: Karel Petrak D Phil. “A Challenge to Artificial Intelligence: Find Molecular Structures Uniquely and Functionally Connected to the Initiation and Progression of Diseases”.Acta Scientific Cancer Biology 4.2 (2020): 01-04.



Member In



News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for March Issue
    The last date for submission of articles for regular Issues is February 29, 2020.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US